[SABCS2014]2014年SABCS AACR乳腺癌杰出研究奖得主——康毅滨教授访谈

作者:  康毅滨   日期:2014/12/13 17:19:02



  Oncology Frontier: Dr. Kang, thank you for joining us. You gave a presentation here, an award winning presentation on metastases, congratulations.


  Dr. Kang: Thank you.


  Oncology Frontier: You talked about the heterogeneity of cells that metastasize. Could you explain that?


  Dr. Kang: So it is known that metastasis is actually a very difficult event for cancer cells. Of all of the millions of cells in circulation, only a tiny fraction is able to make metastases in the end. It is a highly selective process that only the fittest are able to make metastases.


  Oncology Frontier: How do you identify which of those cells are the fittest and target those?


  Dr. Kang: We use a method called in vivo selection, basically using Darwinian selection of the fittest in vivo using a mouse as a platform. We inject human tumor cells in new mice and then follow metastases in the lung, or the bone, or in the brain. The idea is that the ones that make metastases are those fittest cells that have a specific ability to form tumors. We can then isolate sublines in all of them and we validate whether they do have increased ability to make metastases. Once you confirm that, then you have a subline with bonetropic, lungtropic, or braintropic metastatic behavior.


  Oncology Frontier: Identifying those cells is one step but what is the end goal, just because you know what the cell is still want to do something about it.


  Dr. Kang: Yes, I think in the past this was difficult. This was difficult because the in vivo approach is not new. This has been developed pioneer in the field during the 1970s. At that time we are stuck, you have the subline but you do not know what to do with it. We did not even know how many genes are in a genome, and so it is only in the last 10 to 20 years that we have genomics and polynomic studies, and now we have a quick and comprehensive view of the genome with those highly metastatic cells. On top of that, we also have clinical data from patients, so we can test which gene associates with poor outcome patients. We have both genomic advances used to increase accuracy and sensitivity in mouse models, and we also have data from clinical samples. All that combines to allow us to find the genes and validate the importance of metastases in the mouse and the clinical importance in human patients.


[1]  [2]  下一页

版面编辑:张楠  责任编辑:侯丹丹


AACR乳腺癌杰出研究奖 骨转移肿瘤基质相互作用TGFβ

分享到: 更多